来曲唑(letrozole)

Search documents
华人学者最新Cell论文:老药新用显奇效,逆转阿尔茨海默病,恢复记忆力
生物世界· 2025-07-23 02:58
Core Viewpoint - Alzheimer's disease (AD) is a prevalent neurodegenerative disorder with no effective treatment to reverse its progression, necessitating urgent action for better therapeutic options [2][3][6]. Group 1: Current State of Alzheimer's Disease - Over 50 million people globally suffer from Alzheimer's or related dementias, with projections indicating this number will double by 2050 [3]. - Annual global spending on Alzheimer's exceeds $1 trillion, making it one of the most costly health issues [3]. - The drug development landscape for Alzheimer's faces significant challenges, with a failure rate of 98% over recent decades [6]. Group 2: Research Findings - A recent study published in Cell identified two FDA-approved cancer drugs, letrozole and irinotecan, that, when used in combination, significantly improved memory and reduced Alzheimer's-related pathology in mouse models [4][17][20]. - The research utilized publicly available data to analyze gene expression changes in neurons and glial cells associated with Alzheimer's, leading to the identification of potential drug candidates [9][11][20]. - The study highlighted the importance of glial cell dysfunction alongside neuronal vulnerability in the disease's heterogeneous pathology [7][8]. Group 3: Methodology and Results - The research team compared gene expression features from Alzheimer's patients with a drug response database, narrowing down 1,300 drugs to 86, then to 10, and finally to 5 promising candidates [10][13]. - The combination therapy of letrozole and irinotecan was shown to reverse multiple Alzheimer's symptoms in mouse models, eliminating toxic protein plaques and restoring memory [17][20]. - The study emphasizes a cell-type directed, multi-target drug discovery strategy based on human data and real-world evidence, paving the way for precision medicine in Alzheimer's treatment [18][20].